Evidence map›Paper›PMID 41984592›Full record

ArticleSTAR protocols2026

Protocol to identify covalent inhibitors targeting RhoA Cys16.

Tin-Yan Koo, Chloe See-Hang Ho, Hillary Yui-Yan Yip, Clive Yik-Sham Chung

Abstract read
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tin-Yan KooSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong, China. Electronic address: u3548650@connect.hku.hk.
Chloe See-Hang HoSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong, China.
Hillary Yui-Yan YipSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong, China.
Clive Yik-Sham ChungSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong, China; Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong, China; Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China. Electronic address: cyschung@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ras homolog family member A (RhoA) is a therapeutic hotspot in many cancers but remains undruggable. Here, we present a protocol for identifying covalent inhibitors targeting RhoA Cys16. We describe steps for the identification of lead compounds by activity-based protein profiling (ABPP) screening and the validation of engagement by mass spectrometry and chemical biology experiments. We then detail procedures for investigating the effects of the compounds on RhoA signaling in cancer cells and mouse colorectal cancer (CRC) models. For complete details on the use and execution of this protocol, please refer to Koo et al.

Indexed as

CysteinerhoA GTP-Binding ProteinAnimalsCell Line, TumorHumansMass SpectrometryMiceSignal TransductionCysteinerhoA GTP-Binding ProteinCancerCell-based AssaysMolecular/Chemical ProbesProteomics

Identifiers

PMID41984592
PMCPMC13092739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.